Government-Owned Inventions; Availability for Licensing, 30964-30965 [2021-12181]

Download as PDF 30964 Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Zhihong Shan, Ph.D., MD, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 205–J, Bethesda, MD 20892, (301) 827–7085, zhihong.shan@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: June 4, 2021. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. khammond on DSKJM1Z7X2PROD with NOTICES [FR Doc. 2021–12142 Filed 6–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Benjamin Hurley; tel. 240–669–5092; benjamin.hurley@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: SUMMARY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus. Date: July 15, 2021. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208– Z, Bethesda, MD 20892, (301) 827–7987, susan.sunnarborg@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for 17:15 Jun 09, 2021 Dated: June 4, 2021. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. ACTION: [FR Doc. 2021–12138 Filed 6–9–21; 8:45 am] VerDate Sep<11>2014 Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Jkt 253001 FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof for Detecting HIV and SIV Description of Technology Quantitative polymerase chain reactions (qPCRs) are commonly employed to enumerate genes of interest among particular biological samples. Insertion of PCR amplicons into plasmid DNA is a mainstay for creation of known quantities of target sequences to standardize quantitative PCRs. Typically, one amplicon is inserted into one plasmid construct, the plasmid is then amplified, purified, serially diluted, and then quantified to be used to enumerate target sequences in PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 unknown samples. As qPCR is often used to detect multiple amplicons simultaneously, individual qPCR standards are often desired to be normalized one to another. Unlike prior methods using separate plasmid constructs for each target sequence, FRODO incorporates eight amplicons into one plasmid construct ensuring equivalent template copy numbers for all amplicons. Amplifying, purifying, diluting and quantifying one plasmid construct rather than eight individual constructs streamlines standard curve qPCR analyses, reducing reagents and simplifying normalization between amplicons. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • Clinical Detection, Monitoring of Nucleic Acid Markers of HIV and Immunological Health: FRODO may be used to efficiently quantify target sequences in unknown samples. • FRODO is a single plasmid containing 8 amplicons which can be used to quantify several different strains of SIV and HIV, cell number equivalents for humans and nonhuman primates, T cell receptor excision circles (humans and nonhuman primates), and bacterial 16S and ampicillin resistance DNA. • FRODO may offer improved, more affordable, highly-sensitive nucleic acid-based HIV quantification and/or diagnostic response times, enhancing patient treatment and interventions. • FRODO can be used to quantify levels of bacterial DNA in clinical samples to determine potential sepsis. • This technology is especially useful in translational HIV research in which human and nonhuman primate models are used to study HIV pathogenesis, informing public health responses. Competitive Advantages • A simplified workflow for qPCR testing. Amplifying, purifying, diluting and quantifying one plasmid construct rather than multiple, individual constructs streamlines standard curve qPCR analyses, reducing reagents and simplifying normalization between amplicons. • At present, there are a number of antibody-based clinical tools that may be used for diagnosing/detecting HIV, but there are fewer products that affordably detect/monitor nucleic acids of HIV within cells, and immunological health, and efficacy of medicaments E:\FR\FM\10JNN1.SGM 10JNN1 Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices aimed at reducing cells infected with HIV. Inventors: Jason Brenchley and Charlotte Langner, both of NIAID. Publications: Langer, Charlotte A. and Brenchley, Jason M.; Frugally Optimized DNA Octomer (FRODO) qPCR Measurement of HIV and SIV in Human and Nonhuman Primate Samples; Current Protocols, 2021. Intellectual Property: HHS Reference No. E–024–2021; US Provisional Application No. 63/128,392. Licensing Contact: To license this technology, please contact Benjamin Hurley at 240–669–5092 or benjamin.hurley@nih.gov, and reference E–024–2021. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Benjamin Hurley; 240–669– 5092, benjamin.hurley@nih.gov. Dated: June 2, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021–12181 Filed 6–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Summer Institute for Biostatistics. Date: July 15, 2021. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. VerDate Sep<11>2014 17:15 Jun 09, 2021 Jkt 253001 Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Shelley Sehnert, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Suite 208–T, Bethesda, MD 20817, (301) 827–7984, ssehnert@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: June 4, 2021. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–12140 Filed 6–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Computational, Modeling and Biodata Management. Date: July 6, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm 6188, MSC 7804, Bethesda, MD 20892, (301) 435–1267, belangerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Oncology. Date: July 7–8, 2021. Time: 9:00 a.m. to 7:00 p.m. PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 30965 Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Nywana Sizemore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6189, MSC 7804, Bethesda, MD 20892, 301–408– 9916, sizemoren@csr.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Biostatistical Methods and Research Design Study Section. Date: July 7–9, 2021. Time: 9:30 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Victoriya Volkova, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3140, Bethesda, MD 20892, (301) 594–7781, victoriya.volkova@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Synthetic and Biological Chemistry. Date: July 7–8, 2021. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Shan Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–4390, shan.wang@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Oral and Dental Sciences. Date: July 7, 2021. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Chee Lim, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435–1850, limc4@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Biostatistical Methods and Research Design. Date: July 7, 2021. Time: 1:30 p.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Karen Nieves Lugo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 3148, MSC 7770, Bethesda, MD 20892, (301) 594– 9088, karen.nieveslugo@nih.gov. E:\FR\FM\10JNN1.SGM 10JNN1

Agencies

[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30964-30965]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12181]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Benjamin Hurley; tel. 240-669-5092; 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof for 
Detecting HIV and SIV

Description of Technology

    Quantitative polymerase chain reactions (qPCRs) are commonly 
employed to enumerate genes of interest among particular biological 
samples. Insertion of PCR amplicons into plasmid DNA is a mainstay for 
creation of known quantities of target sequences to standardize 
quantitative PCRs. Typically, one amplicon is inserted into one plasmid 
construct, the plasmid is then amplified, purified, serially diluted, 
and then quantified to be used to enumerate target sequences in unknown 
samples. As qPCR is often used to detect multiple amplicons 
simultaneously, individual qPCR standards are often desired to be 
normalized one to another. Unlike prior methods using separate plasmid 
constructs for each target sequence, FRODO incorporates eight amplicons 
into one plasmid construct ensuring equivalent template copy numbers 
for all amplicons. Amplifying, purifying, diluting and quantifying one 
plasmid construct rather than eight individual constructs streamlines 
standard curve qPCR analyses, reducing reagents and simplifying 
normalization between amplicons.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Clinical Detection, Monitoring of Nucleic Acid Markers of 
HIV and Immunological Health: FRODO may be used to efficiently quantify 
target sequences in unknown samples.
     FRODO is a single plasmid containing 8 amplicons which can 
be used to quantify several different strains of SIV and HIV, cell 
number equivalents for humans and nonhuman primates, T cell receptor 
excision circles (humans and nonhuman primates), and bacterial 16S and 
ampicillin resistance DNA.
     FRODO may offer improved, more affordable, highly-
sensitive nucleic acid-based HIV quantification and/or diagnostic 
response times, enhancing patient treatment and interventions.
     FRODO can be used to quantify levels of bacterial DNA in 
clinical samples to determine potential sepsis.
     This technology is especially useful in translational HIV 
research in which human and nonhuman primate models are used to study 
HIV pathogenesis, informing public health responses.

Competitive Advantages

     A simplified workflow for qPCR testing. Amplifying, 
purifying, diluting and quantifying one plasmid construct rather than 
multiple, individual constructs streamlines standard curve qPCR 
analyses, reducing reagents and simplifying normalization between 
amplicons.
     At present, there are a number of antibody-based clinical 
tools that may be used for diagnosing/detecting HIV, but there are 
fewer products that affordably detect/monitor nucleic acids of HIV 
within cells, and immunological health, and efficacy of medicaments

[[Page 30965]]

aimed at reducing cells infected with HIV.
    Inventors: Jason Brenchley and Charlotte Langner, both of NIAID.
    Publications: Langer, Charlotte A. and Brenchley, Jason M.; 
Frugally Optimized DNA Octomer (FRODO) qPCR Measurement of HIV and SIV 
in Human and Nonhuman Primate Samples; Current Protocols, 2021.
    Intellectual Property: HHS Reference No. E-024-2021; US Provisional 
Application No. 63/128,392.
    Licensing Contact: To license this technology, please contact 
Benjamin Hurley at 240-669-5092 or [email protected], and 
reference E-024-2021.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this invention. For collaboration 
opportunities, please contact Benjamin Hurley; 240-669-5092, 
[email protected].

    Dated: June 2, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-12181 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P